| Revision as of 07:33, 15 August 2011 editCheMoBot (talk | contribs)Bots141,565 edits Updating {{chembox}} (no changed fields - added verified revid - updated 'ChemSpiderID_Ref', 'DrugBank_Ref', 'ChEMBL_Ref', 'ChEBI_Ref', 'KEGG_Ref', 'StdInChI_Ref', 'StdInChIKey_Ref', 'ChEBI_Ref') per [[Misplaced Pages:WikiProject Chemicals/Chembox validati← Previous edit |
Latest revision as of 17:10, 1 June 2022 edit undoCitation bot (talk | contribs)Bots5,429,570 edits Add: pages, issue. Removed parameters. | Use this bot. Report bugs. | Suggested by Abductive | #UCB_webform 305/373 |
| (24 intermediate revisions by 19 users not shown) |
| Line 1: |
Line 1: |
|
{{orphan|date=April 2010}} |
|
|
|
|
|
{{chembox |
|
{{chembox |
|
|
| Verifiedfields = changed |
| ⚫ |
| UNII_Ref = {{fdacite|correct|FDA}} |
|
|
|
| Watchedfields = changed |
| ⚫ |
| UNII = B5TAN0L720 |
|
|
| verifiedrevid = 442302656 |
|
| verifiedrevid = 444934628 |
|
| ImageFile = Picoplatin.png |
|
| ImageFile = Picoplatin.png |
|
| ImageSize = 150px |
|
| ImageSize = 150px |
|
| IUPACName = azane; 2-methylpyridine; platinum(2+); dichloride |
|
| IUPACName = azane; 2-methylpyridine; platinum(2+); dichloride |
|
| OtherNames = |
|
| OtherNames = |
|
| Section1 = {{Chembox Identifiers |
|
|Section1={{Chembox Identifiers |
|
⚫ |
| UNII_Ref = {{fdacite|correct|FDA}} |
|
⚫ |
| UNII = B5TAN0L720 |
|
|
| CASNo_Ref = {{cascite|correct|??}} |
|
| CASNo = 181630-15-9 |
|
| CASNo = 181630-15-9 |
|
| PubChem = 177358 |
|
| PubChem = 177358 |
|
|
| ChemSpiderID_Ref = {{chemspidercite|changed|chemspider}} |
| ⚫ |
| SMILES = CC1=CC=CC=N1.N... |
|
|
|
| ChemSpiderID = 154428 |
|
⚫ |
| SMILES = Cc1ccccn1.N... |
|
|
| SMILES_Comment = ionic form |
|
|
| SMILES1 = Cl(Cl)()1ccccc1C |
|
|
| SMILES1_Comment = coordination form |
|
|
| InChI = 1/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2 |
|
|
| InChIKey = IIMIOEBMYPRQGU-NUQVWONBAG |
|
|
| StdInChI_Ref = {{stdinchicite|changed|chemspider}} |
|
|
| StdInChI = 1S/C6H7N.2ClH.H3N.Pt/c1-6-4-2-3-5-7-6;;;;/h2-5H,1H3;2*1H;1H3;/q;;;;+2/p-2 |
|
|
| StdInChIKey_Ref = {{stdinchicite|changed|chemspider}} |
|
|
| StdInChIKey = IIMIOEBMYPRQGU-UHFFFAOYSA-L |
|
}} |
|
}} |
|
| Section2 = {{Chembox Properties |
|
|Section2={{Chembox Properties |
|
| C=6|H=10|Cl=2|N=2|Pt=1 |
|
| C=6 | H=10 | Cl=2 | N=2 | Pt=1 |
|
| Appearance = |
|
| Appearance = |
|
| Density = |
|
| Density = |
| Line 21: |
Line 33: |
|
| BoilingPt = |
|
| BoilingPt = |
|
| Solubility = }} |
|
| Solubility = }} |
|
| Section3 = {{Chembox Hazards |
|
|Section3={{Chembox Hazards |
|
| MainHazards = |
|
| MainHazards = |
|
| FlashPt = |
|
| FlashPt = |
|
| Autoignition = }} |
|
| AutoignitionPt = }} |
|
}} |
|
}} |
|
|
|
|
|
'''Picoplatin''' is a ] ] compound in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid ]s<ref>. |
|
'''Picoplatin''' is a ] in clinical development by Poniard Pharmaceuticals (previously NeoRx) for the treatment of patients with solid ]s.<ref>{{cite journal | doi = 10.1039/C0DT00292E | volume=39 | title=The status of platinum anticancer drugs in the clinic and in clinical trials | year=2010 | journal=Dalton Transactions | last1 = Wheate | first1 = Nial J.| issue=35 | pages=8113–8127 | url=https://ses.library.usyd.edu.au/bitstream/2123/9269/2/41%20Dalton%20perspective.pdf | pmid=20593091 | hdl=2123/14271 | hdl-access=free }}</ref> |
|
|
|
|
|
In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.<ref>, Poniard Pharmaceuticals</ref> However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced ].<ref>, fiercebiotech.com, November 16, 2009</ref> Hopes are now pinned on its use for metastatic ]<ref>http://www.genengnews.com/specialreports/sritem.aspx?oid=69418732 Nov 2009</ref>. |
|
In Phase I and Phase II clinical trials, picoplatin demonstrated activity in a variety of solid tumors, including lung, ovarian, colorectal and hormone-refractory prostate cancer.<ref>, Poniard Pharmaceuticals</ref> However, in Phase III trials, picoplatin failed to hit its primary endpoint for advanced ].<ref>, fiercebiotech.com, November 16, 2009</ref> Hopes are now pinned on its use for metastatic ].<ref>http://www.genengnews.com/specialreports/sritem.aspx?oid=69418732 Nov 2009</ref> |
|
|
|
|
|
== References == |
|
== References == |
|
{{Reflist}} |
|
{{Reflist}} |
|
⚫ |
{{Platinum compounds}} |
|
|
|
|
|
] |
|
] |
| ⚫ |
] |
|
|
] |
|
] |
|
] |
|
] |
|
|
] |
|
|
|
|
|
|
|
|